Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Raises Full-Year Projections on Higher Q2 MassArray Sales

NEW YORK (GenomeWeb News) - Sequenom yesterday said second-quarter revenue jumped 41 percent as R&D spending climbed 79 percent and net loss grew 23 percent.
Total receipts for the three months ended June 30, 2007 rose to $10.2 million from $7.2 million year over year.
"We are executing well against our growth strategy, resulting in a greater than 40 percent revenue increase for the second quarter, compared with the same period last year, due to increased MassArray product and services sales," CEO Harry Stylli said in a statement.
Sequenom said sales of consumables rose 22 percent to $3.8 million from $3.1 million, and other product-related sales increased 38 percent, contributing $5.4 million to second-quarter revenue.
Services sales were up nearly 400 percent to $941,000 from $190,000 from the year-ago period.
R&D spending increased to $4.3 million from $2.5 million year over year.
The company said its net loss grew to $4.8 million from $3.9 million in the year-ago quarter.
Sequenom adjusted its revenue expectations for the full-year 2007 upward by between 37 percent and 44 percent. It now expects to see between $39 million and $41 million in revenue for the year.
The company also lowered its net loss forecast for the year to between $19 million and $21 million from its previously estimated range of $23 million to $25 million.
Sequenom said it had $35 million in cash, cash equivalents, short-term investments and restricted cash as of June 30, 2007.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.